pared with other commercial efforts for ovarian cancer testing. We will continue to post all raw data, the exact methods, and the results of the blinded trial(s) for public scrutiny. These are very important times for biomarker discovery and validation. In keeping with the National Cancer Institute Director’s 2015 challenge, effective biomarkers for early detection, risk stratification, and monitoring can save lives and reduce suffering.

Both Dr. Liotta and Dr. Petricoin are co-inventors on US Government Patent filings that cover technologies described in this reply. As such, under US Government law, the co-inventors may receive royalties on these patent filings once granted and/or licensed. However, US Government scientists are not allowed to participate in licensing negotiations and royalty rate negotiations.

References
7. Petricoin EF, Fishman DA, Conrads TP, Venstra TD, Liotta LA Proteomic pattern diagnostics: producers and consumers in the era of correla

Emanuel F. Petricoin1* Lance A. Liotta2*
1 Clinical Proteomics Program Office of Cell and Gene Therapy
2 NCI/FDA Clinical Proteomics Program Laboratory of Pathology Center for Cancer Research National Cancer Institute Bethesda, MD

Center for Biologics Evaluation and Research Food and Drug Administration Bethesda, MD

2 NCI/FDA Clinical Proteomics Program Laboratory of Pathology Center for Cancer Research National Cancer Institute Bethesda, MD

*Address correspondence to Dr. Petricoin at: CBER/FDA, Bldg. 29A/2D12, 8800 Rockville Pike, Bethesda, MD 20892. Fax 301-480-5005; e-mail petricoin@cber.fda.gov; or Dr. Liotta at: CCR/NCI/NIH, 10 Center Drive, Bethesda, MD 20892; e-mail liotta@mail.nih.gov.

DOI: 10.1373/clinchem.2004.035097

Serum 99th Percentile Reference Cutoffs for Seven Cardiac Troponin Assays

To the Editor:
Several international expert panels, including the European Society of Cardiology, the American College of Cardiology, American Heart Association, the IFCC, the COURAGE trials group, the Italian Federation of Cardiology, and the American Heart Association and World Heart Federation Councils on Epidemiology and Prevention, have endorsed the concept that increased cardiac troponin I or T (cTnl or cTnT) should be defined as a measurement above the 99th percentile concentration of a reference population (1–7). Furthermore, an increased cTnl or cTnT value is considered indicative of myocardial injury (cell death) and, in the clinical setting of ischemia, is considered evidence of myocardial infarction and a high-risk profile for adverse cardiac and noncardiac events.

Previously, work from our laboratory reported on heparin plasma 99th percentile reference limits for both cTnT and seven cTnl assays (8). However, because heparin plasma is known to cause a negative bias compared with some, but not all cTnl and cTnT assays, reference limit determinations in serum would also be useful because serum and heparin plasma are the most commonly used specimen types in clinical practice. Preanalytical considerations suggest the use of plasma for reducing turnaround times. In addition, a recent study of imprecision for cardiac troponin assays to determine the lowest concentration that meets a 10% total imprecision (CV) was predicated on serum (9), with the goal to assess the size of the gap between the 99th percentile reference limit and the lowest troponin concentration that provides a 10% CV.

Although several studies have published serum-based 99th percentile reference limits for individual assays, no study has used the same population to evaluate reference limits for numerous cardiac troponin assays. The purpose of this study was to determine (using nonparametric statistics) the 99th percentile reference limit, based on samples from 403 healthy volunteers.

After receiving Institutional Review Board approval and having participants complete a health questionnaire ruling out any past or current history of heart disease, we collected nonanticoagulated blood (Becton Dickinson Vacutainer SST Gel and Clot Activator tube), separated the serum, and froze it at −70°C. We recruited 215 females (53%) and 188 (47%) males, of whom 168 were African American (42%), 181 were Caucasian (45%), and 54 were of other ethnicities (13%). Ages ranged from 30 to 84 years (median, 49 years). As shown in Table 1, not all assays were performed on all samples because of limited specimen volumes. To verify lack of interference by heterophile antibodies, we screened selected samples with high cardiac troponin by a commercial heterophile antibody blocking system (Scantibodies Laboratories). Shown in Table 1 are the serum 99th percentile reference limits for six cTnl assays and one cTnT assay for all participants, as well as a breakdown for males and females.

For cTnl, the reference limits ranged from 0.03 µg/L (Dade Dimension) to 1.1 µg/L (Abbott AxSYM), a
36-fold difference. We found significant differences between males and females for the Beckman Access, Ortho cTnI Vitros ECI, and Bayer Centaur cTnI assays. All cTnT concentrations were \( \leq 0.015 \mu g/L \), with the overall 99th percentile limit being \( <0.01 \mu g/L \). Only the Ortho Vitros ECI cTnI showed a significant difference by ethnicity.

Our results for serum are similar to those obtained in our previous study on 99th percentile reference limits for plasma (8); (a) results obtained with different cTnI assays vary considerably because of differences in standardization and in the antibodies used (10); and (b) there is evidence of gender and ethnic variation. In general, the current serum reference concentrations (\( n \approx 403 \) individuals) compared with our previous plasma findings in a larger population (\( n \approx 696 \) individuals) were not predictably higher for all assays, as has been suggested in several Food and Drug Administration-cleared package inserts and previous literature (4, 8, 11, 12). The findings also demonstrate that only one of seven assays (Beckman) gave a 99th percentile concentration (0.05 \( \mu g/L \)) close to the previously reported total 10% imprecision concentration (0.06 \( \mu g/L \)) (9). Thus it is possible that some of the gender differences may be related to assay imprecision. A limitation of this study, however, was that matched serum and plasma samples were not available for analysis. Overall, our findings add to the literature to assist in setting reference limits for the cardiac troponin assays available from the major in vitro diagnostic manufacturers. Further investigations are necessary to explore gender and ethnic differences that may impact diagnostic or risk stratification decisions in patients with acute coronary syndrome (13–17).

### References

### Table 1. Serum 99th percentile reference limits by gender and ethnicity for Food and Drug Administration-cleared cardiac troponin assays.

<table>
<thead>
<tr>
<th></th>
<th>n</th>
<th>Abbott</th>
<th>Beckman</th>
<th>Dade</th>
<th>OC&amp;D</th>
<th>Roche&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Tosoh</th>
<th>Bayer</th>
</tr>
</thead>
<tbody>
<tr>
<td>All participants</td>
<td>374</td>
<td>1.1</td>
<td>0.05</td>
<td>0.03</td>
<td>0.29</td>
<td>&lt;0.01</td>
<td>0.13</td>
<td>(n = 403)</td>
</tr>
<tr>
<td>Males</td>
<td>189</td>
<td>1.1</td>
<td>0.06</td>
<td>0.03</td>
<td>0.44</td>
<td>0.015</td>
<td>0.13</td>
<td>(n = 201)</td>
</tr>
<tr>
<td>Females</td>
<td>185</td>
<td>0.6</td>
<td>0.03</td>
<td>0.02</td>
<td>0.15</td>
<td>&lt;0.01</td>
<td>0.13</td>
<td>(n = 202)</td>
</tr>
<tr>
<td>P (males vs females)</td>
<td>0.7</td>
<td>&lt;0.001</td>
<td>0.4</td>
<td>0.007</td>
<td>0.3</td>
<td>0.13</td>
<td>0.13</td>
<td>0.08</td>
</tr>
<tr>
<td>Caucasians</td>
<td>216</td>
<td>1.1</td>
<td>0.05</td>
<td>0.02</td>
<td>0.10</td>
<td>&lt;0.01</td>
<td>0.13</td>
<td>(n = 215)</td>
</tr>
<tr>
<td>Blacks</td>
<td>154</td>
<td>1.2</td>
<td>0.05</td>
<td>0.04</td>
<td>0.44&lt;sup&gt;c&lt;/sup&gt;</td>
<td>&lt;0.01</td>
<td>0.15</td>
<td>(n = 162)</td>
</tr>
<tr>
<td>P (Caucasians vs blacks)</td>
<td>0.3</td>
<td>0.2</td>
<td>0.31</td>
<td>0.05</td>
<td>0.5</td>
<td>0.08</td>
<td>0.4</td>
<td></td>
</tr>
</tbody>
</table>

*Not all assays were performed on all samples because of insufficient sample volume. The number of samples assayed with the Tosoh and Bayer assays are shown in parentheses when they differ from the number of samples tested by the other assays.

<sup>a</sup> Only cTnT assay on the marketplace; all other assays are for cTnI.

<sup>c</sup> Significantly different (\( P = 0.05 \)) vs Caucasians based on mean concentrations.
three sites of DNA polymorphisms in UGT1A1 (UGT1A1*28, UGT1A1*6, and UGT1A1*27) by the previously described method (1). UGT1A1*28 was distinguished from the most common allele (UGT1A1*1) by direct sequencing (nucleotides –147 to +106) of the 253- to 255-bp fragments produced by PCR. UGT1A1*6 and UGT1A1*27 were distinguished from UGT1A1*1 by direct sequencing combined with PCR-restriction fragment length polymorphism (RFLP) analysis.

The Invader assay detects single-nucleotide polymorphisms (SNPs) by use of Cleavase enzyme and a fluorescence resonance energy transfer cassette (2, 3). Two sets of probes were designed for detecting the SNPs associated with UGT1A1*6 and *27 (see Table 1 in the Data Supplement that accompanies the online version of this letter at http://www.clinchem.org/content/vol50/issue8/). The UGT1A1*6 target site was +211G/A, and the *27 target site was +686C/A. In addition, a set of probes was designed to differentiate between the UGT1A1*28 polymorphism and its reference allele (UGT1A1*1; Table 1 in the online Data Supplement) based on the number of TA repeats; UGT1A1*28 has seven TA repeats, and UGT1A1*1 has six. An important portion of the probe was designed with the help of Third Wave Technologies, Inc. With these detection systems, the reference and variant alleles are indicated by the Redmond Red (Epoch Biosciences) and 6-carboxyfluorescein (FAM) fluorescent signals, respectively, which were released from the fluorescence resonance energy transfer cassette.

The 60 samples included 4 homozygous [(TA)2/ (TA)2] and 11 heterozygous [(TA)2/ (TA)n] for UGT1A1*28; the remaining 45 samples were homozygous for the reference allele [(TA)n/ (TA)n]. The distribution of genotypes showed 1 homozygous and 17 heterozygous for UGT1A1*6 and 42 homozygous for the reference allele. Two samples heterozygous for UGT1A1*27 and 58 homozygous for the reference allele were assayed. These data were determined by direct DNA sequencing of UGT1A1*28 and by direct DNA sequencing combined with PCR-RFLP analysis for UGT1A1*6 and UGT1A1*27, and the results obtained from the Invader assay were compared with them (see Table 2 in the online Data Supplement).

Three of the 60 samples could not be assayed for UGT1A1*28 by the Invader assay. These samples showed low fluorescence intensity because of their small genomic DNA content (DNA concentration, 15 ng/10 μL, 16 ng/10 μL, and 21 ng/10 μL, respectively). The minimum input of DNA for which UGT1A1*28 was measured by the Invader assay was 21 ng/10 μL. The genotyping of 57 samples measured by the Invader assay agreed completely with the results obtained by direct DNA sequencing. Six of the 60 samples could not be measured for UGT1A1*6 by the Invader assay. These samples showed low fluorescence intensity because of the small content of genomic DNA (content, per 10 μL, of 15, 16, 21, 21, 38, and 46 ng, respectively). The minimum input of DNA for which UGT1A1*6 was measured by the Invader assay was 29 ng/10 μL. The results for the remaining samples obtained by the Invader assay agreed well with those obtained by the PCR-RFLP assay.

Forty-seven of the 60 samples were genotyped correctly for UGT1A1*27 by the Invader assay, and the results were consistent with those obtained by the PCR-RFLP assay. Three samples could not be measured by the Invader assay because of their low fluorescence intensity (DNA per 10 μL, 15, 16, and 21 ng, respectively). In addition, 10 samples could not be measured because of an indistinct fluorescence signal ratio (range, 2.861–4.995; median, 4.718; Table 1 in the online Data Supplement). These samples also contained small amounts of genomic DNA (range, 21–59 ng/10 μL; median, 44 ng/10 μL). Thirty-nine samples containing genomic DNA >60 ng/μL were correctly genotyped by the Invader assay. The minimum input of DNA for which UGT1A1*27 was measured by the Invader assay was 39 ng/10 μL.

Rapid Detection of UGT1A1 Gene Polymorphisms by Newly Developed Invader Assay

To the Editor:

Recent progress in human genome analysis has been providing tools for a new approach to disease treatment based on individual differences identified by use of genetic information. The feasibility of genotyping for DNA polymorphisms before treatment depends on the availability of rapid, accurate, and efficient genotyping methods. We previously reported that genetic polymorphisms of the UDP-glucuronosyltransferase 1A1 (UGT1A1) gene were significantly related to severe toxicity of irinotecan (1). We now report that we have succeeded in detecting a 2-bp insertion of repeated sequence in the UGT1A1 gene by use of Invader assay technology.

Sixty patients who had received irinotecan-containing chemotherapy from July 1994 to June 1999 were enrolled in this study. All gave informed consent in writing for their peripheral blood to be used for the research. We used the QIAamp Blood Kit (QIAGEN GmbH) to prepare genomic DNA from whole blood (100–200 μL) and genotyped